{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:34:39Z","timestamp":1790274879847,"version":"4.1.0"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.diabres.2020.108199","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T21:31:37Z","timestamp":1589319097000},"page":"108199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Stroke in the patient with diabetes (Part 2) \u2013 Prevention and the effects of glucose lowering therapies"],"prefix":"10.1016","volume":"164","author":[{"given":"David S.H.","family":"Bell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edison","family":"Goncalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3 Suppl 2","key":"10.1016\/j.diabres.2020.108199_b0005","first-page":"S5","article-title":"The global burden of stroke and need for a continuum of care","volume":"80","author":"Norrving","year":"2013","journal-title":"Neurology"},{"issue":"16","key":"10.1016\/j.diabres.2020.108199_b0010","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1056\/NEJMoa1310799","article-title":"Changes in diabetes-related complications in the United States, 1990\u20132010","volume":"370","author":"Gregg","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.diabres.2020.108199_b0015","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/dom.13512","article-title":"Atrial fibrillation and type 2 diabetes: prevalence, etiology, pathophysiology and effect of anti-diabetic therapies","volume":"21","author":"Bell","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.diabres.2020.108199_b0020","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1111\/dom.13371","article-title":"Should we still be utilizing warfarin in the type 2 diabetic patient?","volume":"20","author":"Bell","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 1","key":"10.1016\/j.diabres.2020.108199_b0025","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.2337\/dc18-S009","article-title":"9. Cardiovascular disease and risk management: standards of medical care in diabetes-2018","volume":"41","author":"American Diabetes A","year":"2018","journal-title":"Diabetes Care"},{"issue":"16","key":"10.1016\/j.diabres.2020.108199_b0030","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1093\/eurheartj\/ehm248","article-title":"AHA\/ADA vs. ESC\/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions","volume":"28","author":"Nicolucci","year":"2007","journal-title":"Eur Heart J"},{"issue":"18","key":"10.1016\/j.diabres.2020.108199_b0035","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1001\/jama.2008.623","article-title":"Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial","volume":"300","author":"Ogawa","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.diabres.2020.108199_b0040","doi-asserted-by":"crossref","first-page":"a1840","DOI":"10.1136\/bmj.a1840","article-title":"The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease","volume":"337","author":"Belch","year":"2008","journal-title":"BMJ"},{"issue":"16","key":"10.1016\/j.diabres.2020.108199_b0045","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"Group ASC","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.diabres.2020.108199_b0050","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.2337\/dc18-er06a","article-title":"Erratum. Aspirin for the primary prevention of cardiovascular events. A systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care 2009;32:2300-2306","volume":"41","author":"Calvin","year":"2018","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.diabres.2020.108199_b0055","doi-asserted-by":"crossref","first-page":"e90286","DOI":"10.1371\/journal.pone.0090286","article-title":"Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status","volume":"9","author":"Xie","year":"2014","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.diabres.2020.108199_b0060","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.2337\/dc10-0555","volume":"33","author":"Pignone","year":"2010","journal-title":"Diabetes Care"},{"issue":"10186","key":"10.1016\/j.diabres.2020.108199_b0065","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/S0140-6736(19)30541-0","article-title":"The rise and fall of aspirin in the primary prevention of cardiovascular disease","volume":"393","author":"Raber","year":"2019","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.diabres.2020.108199_b0070","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMe1812000","article-title":"Should aspirin be used for primary prevention in the post-statin era?","volume":"379","author":"Ridker","year":"2018","journal-title":"N Engl J Med"},{"issue":"7329","key":"10.1016\/j.diabres.2020.108199_b0075","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Antithrombotic","year":"2002","journal-title":"BMJ"},{"issue":"10042","key":"10.1016\/j.diabres.2020.108199_b0080","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(16)30468-8","article-title":"Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials","volume":"388","author":"Rothwell","year":"2016","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.diabres.2020.108199_b0085","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1212\/01.WNL.0000118288.04483.02","article-title":"Antiplatelet drug discontinuation is a risk factor for ischemic stroke","volume":"62","author":"Sibon","year":"2004","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.diabres.2020.108199_b0090","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1080\/00325481.2016.1131106","article-title":"Aspirin in the prevention of cardiovascular events in patients with diabetes","volume":"128","author":"Bell","year":"2016","journal-title":"Postgrad Med."},{"issue":"7","key":"10.1016\/j.diabres.2020.108199_b0095","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3109\/07853890.2011.582137","article-title":"Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention","volume":"43","author":"Di Minno","year":"2011","journal-title":"Ann. Med."},{"issue":"18","key":"10.1016\/j.diabres.2020.108199_b0100","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1161\/CIRCULATIONAHA.115.016783","article-title":"Diabetes mellitus and prevention of late myocardial infarction after coronary stenting in the randomized dual antiplatelet therapy study","volume":"133","author":"Meredith","year":"2016","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.diabres.2020.108199_b0105","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.diabres.2020.108199_b0110","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.2876","article-title":"Safety and efficacy of nonvitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: a study-level meta-analysis of phase III randomized trials","volume":"33","author":"Patti","year":"2017","journal-title":"Diabetes Metab Res Rev."},{"issue":"1","key":"10.1016\/j.diabres.2020.108199_b0115","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1160\/TH17-02-0095","article-title":"Is there a preferred stroke prevention strategy for diabetic patients with non-valvular atrial fibrillation? Comparing Warfarin, Dabigatran and Rivaroxaban","volume":"118","author":"Hsu","year":"2018","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.diabres.2020.108199_b0120","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jacc.2016.10.069","article-title":"Insulin-requiring versus noninsulin-requiring diabetes and thromboembolic risk in patients with atrial fibrillation: PREFER in AF","volume":"69","author":"Patti","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.diabres.2020.108199_b0125","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jacc.2016.11.030","article-title":"Insulin therapy and stroke risk in patients with diabetes and atrial fibrillation: guilty by association?","volume":"69","author":"Piccini","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.diabres.2020.108199_b0130","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00125-017-4422-0","article-title":"DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality","volume":"61","author":"Pieber","year":"2018","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.diabres.2020.108199_b0135","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1210\/jc.2012-3042","article-title":"Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes","volume":"98","author":"Currie","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.diabres.2020.108199_b0140","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/pds.3914","article-title":"Case-control study of oral glucose-lowering drugs in combination with long-acting insulin and the risks of incident myocardial infarction and incident stroke","volume":"25","author":"Floyd","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"10.1016\/j.diabres.2020.108199_b0145","doi-asserted-by":"crossref","first-page":"601","DOI":"10.7326\/0003-4819-157-9-201211060-00003","article-title":"Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study","volume":"157","author":"Roumie","year":"2012","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.diabres.2020.108199_b0150","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/dom.12821","article-title":"Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: a Bayesian meta-analysis of survival data","volume":"19","author":"Bain","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2020.108199_b0155","doi-asserted-by":"crossref","unstructured":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):837\u201353.","DOI":"10.1016\/S0140-6736(98)07019-6"},{"issue":"16","key":"10.1016\/j.diabres.2020.108199_b0160","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1056\/NEJMoa1001122","article-title":"Effect of nateglinide on the incidence of diabetes and cardiovascular events","volume":"362","author":"Group","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2020.108199_b0165","article-title":"Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.diabres.2020.108199_b0170","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jama.2016.9400","article-title":"Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis","volume":"316","author":"Palmer","year":"2016","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.diabres.2020.108199_b0175","doi-asserted-by":"crossref","first-page":"e1001204","DOI":"10.1371\/journal.pmed.1001204","article-title":"Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials","volume":"9","author":"Boussageon","year":"2012","journal-title":"PLoS Med"},{"issue":"23","key":"10.1016\/j.diabres.2020.108199_b0180","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.diabres.2020.108199_b0185","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2337\/diacare.28.3.539","article-title":"Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study","volume":"28","author":"Cryer","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2020.108199_b0190","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12933-015-0304-2","article-title":"Effect of metformin monotherapy on cardiovascular diseases and mortality: a retrospective cohort study on Chinese type 2 diabetes mellitus patients","volume":"14","author":"Fung","year":"2015","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"10.1016\/j.diabres.2020.108199_b0195","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1210\/jc.2014-2443","article-title":"Cardiovascular risk associated with acarbose versus metformin as the first-line treatment in patients with type 2 diabetes: a nationwide cohort study","volume":"100","author":"Chang","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.diabres.2020.108199_b0200","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/CIRCULATIONAHA.119.040144","article-title":"Metformin use and clinical outcomes among patients with diabetes mellitus with or without heart failure or kidney dysfunction: observations from the SAVOR-TIMI 53 trial","volume":"140","author":"Bergmark","year":"2019","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.diabres.2020.108199_b0205","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/dmrr.2433","article-title":"Effect of acarbose to delay progression of carotid intima-media thickness in early diabetes","volume":"29","author":"Patel","year":"2013","journal-title":"Diabetes Metab Res Rev"},{"issue":"6","key":"10.1016\/j.diabres.2020.108199_b0210","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00125-004-1409-4","article-title":"Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data","volume":"47","author":"Chiasson","year":"2004","journal-title":"Diabetologia."},{"issue":"11","key":"10.1016\/j.diabres.2020.108199_b0215","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2213-8587(17)30309-1","article-title":"Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial","volume":"5","author":"Holman","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.diabres.2020.108199_b0220","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/CIRCULATIONAHA.112.000678","article-title":"Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial","volume":"128","author":"Bach","year":"2013","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.diabres.2020.108199_b0225","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1161\/01.STR.0000257974.06317.49","article-title":"Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)","volume":"38","author":"Wilcox","year":"2007","journal-title":"Stroke"},{"issue":"5","key":"10.1016\/j.diabres.2020.108199_b0230","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1161\/CIRCULATIONAHA.117.030458","article-title":"Pioglitazone prevents stroke in patients with a recent transient ischemic attack or ischemic stroke: a planned secondary analysis of the IRIS trial (insulin resistance intervention after stroke)","volume":"137","author":"Yaghi","year":"2018","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.diabres.2020.108199_b0235","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1111\/dom.13344","article-title":"Impact of treatment with pioglitazone on stroke outcomes: a real-world database analysis","volume":"20","author":"Morgan","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"22","key":"10.1016\/j.diabres.2020.108199_b0240","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.diabres.2020.108199_b0245","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/STROKEAHA.116.015756","article-title":"Empagliflozin and cerebrovascular events in patients with type 2 diabetes mellitus at high cardiovascular risk","volume":"48","author":"Zinman","year":"2017","journal-title":"Stroke"},{"issue":"7","key":"10.1016\/j.diabres.2020.108199_b0250","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.diabres.2020.108199_b0255","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1161\/STROKEAHA.118.023009","article-title":"Canagliflozin and stroke in type 2 diabetes mellitus","volume":"50","author":"Zhou","year":"2019","journal-title":"Stroke"},{"issue":"15","key":"10.1016\/j.diabres.2020.108199_b0260","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.118.035901","article-title":"Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function","volume":"138","author":"Neuen","year":"2018","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.diabres.2020.108199_b0265","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease","volume":"137","author":"Wanner","year":"2018","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.diabres.2020.108199_b0270","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.diabres.2020.108199_b0275","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1161\/CIRCULATIONAHA.119.039996","article-title":"Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction","volume":"139","author":"Furtado","year":"2019","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.diabres.2020.108199_b0280","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.diabres.2020.108199_b0285","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1111\/dom.13299","article-title":"Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: results from the CVD-REAL study","volume":"20","author":"Kosiborod","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"23","key":"10.1016\/j.diabres.2020.108199_b0290","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.diabres.2020.108199_b0295","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.diabres.2020.108199_b0300","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.diabres.2020.108199_b0305","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"issue":"10157","key":"10.1016\/j.diabres.2020.108199_b0310","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2020.108199_b0315","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.diabres.2020.108199_b0320","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/ene.13905","article-title":"Protection against stroke with glucagon-like peptide 1 receptor agonists: a systematic review and meta-analysis","volume":"26","author":"Barkas","year":"2019","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.1016\/j.diabres.2020.108199_b0325","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/dom.13553","article-title":"Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: rationale, design and patient baseline characteristics for the PIONEER 6 trial","volume":"21","author":"Bain","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"10.1016\/j.diabres.2020.108199_b0330","doi-asserted-by":"crossref","first-page":"21513","DOI":"10.3390\/ijms141121513","article-title":"Neuroprotective effects of liraglutide for stroke model of rats","volume":"14","author":"Sato","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.diabres.2020.108199_b0335","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.neuroscience.2014.09.064","article-title":"Neuroprotective and anti-apoptotic effects of liraglutide in the rat brain following focal cerebral ischemia","volume":"281","author":"Briyal","year":"2014","journal-title":"Neuroscience"},{"issue":"8","key":"10.1016\/j.diabres.2020.108199_b0340","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/jcbfm.2011.51","article-title":"Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia","volume":"31","author":"Teramoto","year":"2011","journal-title":"J Cereb Blood Flow Metab"},{"issue":"8","key":"10.1016\/j.diabres.2020.108199_b0345","doi-asserted-by":"crossref","first-page":"e103114","DOI":"10.1371\/journal.pone.0103114","article-title":"Exendin-4 reduces ischemic brain injury in normal and aged type 2 diabetic mice and promotes microglial M2 polarization","volume":"9","author":"Darsalia","year":"2014","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.diabres.2020.108199_b0350","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/WNR.0000000000000046","article-title":"Related expressional change of HIF-1alpha to the neuroprotective activity of exendin-4 in transient global ischemia","volume":"25","author":"Jin","year":"2014","journal-title":"NeuroReport"},{"issue":"5","key":"10.1016\/j.diabres.2020.108199_b0355","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/jcbfm.2015.17","article-title":"Glucagon-like receptor 1 agonists and DPP-4 inhibitors: potential therapies for the treatment of stroke","volume":"35","author":"Darsalia","year":"2015","journal-title":"J Cereb Blood Flow Metab"},{"issue":"14","key":"10.1016\/j.diabres.2020.108199_b0360","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.diabres.2020.108199_b0365","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.diabres.2020.108199_b0370","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822720304496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822720304496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:13:47Z","timestamp":1759173227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822720304496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":74,"alternative-id":["S0168822720304496"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2020.108199","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stroke in the patient with diabetes (Part 2) \u2013 Prevention and the effects of glucose lowering therapies","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2020.108199","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108199"}}